The glucagon-like peptide 1 receptor agonist liraglutide attenuates placental ischemia-induced hypertension

• Published in: American journal of physiology. Heart and circulatory physiology Vol. 318; no. 1; pp. H72 - H77
• Main Authors: Younes, Subhi Talal, Maeda, Kenji J., Sasser, Jennifer, Ryan, Michael J.
• Format: Journal Article
• Language: English
• Published: United States American Physiological Society 01.01.2020
• Series: Integrative Cardiovascular Physiology and Pathophysiology
• Subjects: Agonists; Animals; Animals, Newborn; Antidiabetics; Antihypertensive Agents - pharmacology; Antihypertensive Agents - toxicity; Appetite Regulation - drug effects; Birth Weight - drug effects; Blood pressure; Blood Pressure - drug effects; Diabetes mellitus; Disease Models, Animal; Female; Food intake; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptide-1 Receptor - metabolism; Hypertension; Ischemia; Ischemia - complications; Ischemia - drug therapy; Ischemia - metabolism; Ischemia - physiopathology; Liraglutide - pharmacology; Liraglutide - toxicity; Nitric oxide; Nitric Oxide - metabolism; Nitric Oxide Synthase Type III - metabolism; Nitric-oxide synthase; NOS3 protein; Peptides; Perfusion; Placenta; Placenta - blood supply; Pre-eclampsia; Pre-Eclampsia - etiology; Pre-Eclampsia - metabolism; Pre-Eclampsia - physiopathology; Pre-Eclampsia - prevention & control; Preeclampsia; Pregnancy; Rats; Regional Blood Flow; Renal function; Signal Transduction; Uterus; nitric oxide; GLP-1; preeclampsia; pregnancy

Preeclampsia is a hypertensive disorder of pregnancy characterized by systemic perturbations of nitric oxide function, reflective of generalized endothelial dysfunction. Therapies that target the nitric oxide pathway have shown promise in both clinical and preclinical studies of preeclampsia. The gl...